BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27079849)

  • 1. Rational Design of Proteasome Inhibitors as Antimalarial Drugs.
    Le Chapelain C; Groll M
    Angew Chem Int Ed Engl; 2016 May; 55(22):6370-2. PubMed ID: 27079849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.
    Zhan W; Zhang H; Ginn J; Leung A; Liu YJ; Michino M; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Yukawa T; Chelebieva S; Tumwebaze PK; Lafuente-Monasterio MJ; Martinez-Martinez MS; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Meinke PT; Nathan CF; Kirkman LA; Lin G
    Angew Chem Int Ed Engl; 2021 Apr; 60(17):9279-9283. PubMed ID: 33433953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.
    Li H; Bogyo M; da Fonseca PC
    FEBS J; 2016 Dec; 283(23):4238-4243. PubMed ID: 27286897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
    Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M
    Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-resolution cryo-EM proteasome structures in drug development.
    Morris EP; da Fonseca PCA
    Acta Crystallogr D Struct Biol; 2017 Jun; 73(Pt 6):522-533. PubMed ID: 28580914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of potent and selective non-covalent inhibitors of the Plasmodium falciparum proteasome.
    Li H; Tsu C; Blackburn C; Li G; Hales P; Dick L; Bogyo M
    J Am Chem Soc; 2014 Oct; 136(39):13562-5. PubMed ID: 25226494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity.
    LaMonte GM; Almaliti J; Bibo-Verdugo B; Keller L; Zou BY; Yang J; Antonova-Koch Y; Orjuela-Sanchez P; Boyle CA; Vigil E; Wang L; Goldgof GM; Gerwick L; O'Donoghue AJ; Winzeler EA; Gerwick WH; Ottilie S
    J Med Chem; 2017 Aug; 60(15):6721-6732. PubMed ID: 28696697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of Asparagine Ethylenediamines as Anti-malarial
    Zhan W; Visone J; Ouellette T; Harris JC; Wang R; Zhang H; Singh PK; Ginn J; Sukenick G; Wong TT; Okoro JI; Scales RM; Tumwebaze PK; Rosenthal PJ; Kafsack BFC; Cooper RA; Meinke PT; Kirkman LA; Lin G
    J Med Chem; 2019 Jul; 62(13):6137-6145. PubMed ID: 31177777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
    Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
    Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trioxaferroquines as new hybrid antimalarial drugs.
    Bellot F; Coslédan F; Vendier L; Brocard J; Meunier B; Robert A
    J Med Chem; 2010 May; 53(10):4103-9. PubMed ID: 20443628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome as a target to combat malaria: hits and misses.
    Krishnan KM; Williamson KC
    Transl Res; 2018 Aug; 198():40-47. PubMed ID: 30009761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enantiomeric 1,2,4-trioxanes display equivalent in vitro antimalarial activity versus Plasmodium falciparum malaria parasites: implications for the molecular mechanism of action of the artemisinins.
    O'Neill PM; Rawe SL; Borstnik K; Miller A; Ward SA; Bray PG; Davies J; Oh CH; Posner GH
    Chembiochem; 2005 Nov; 6(11):2048-54. PubMed ID: 16222725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
    Stokes BH; Yoo E; Murithi JM; Luth MR; Afanasyev P; da Fonseca PCA; Winzeler EA; Ng CL; Bogyo M; Fidock DA
    PLoS Pathog; 2019 Jun; 15(6):e1007722. PubMed ID: 31170268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Small Molecules Disrupting the Ubiquitin Proteasome System in Malaria.
    Mata-Cantero L; Chaparro MJ; Colmenarejo G; Cid C; Cortes Cabrera A; Rodriguez MS; Martín J; Gamo FJ; Gomez-Lorenzo MG
    ACS Infect Dis; 2019 Dec; 5(12):2105-2117. PubMed ID: 31644867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimalarials: Novel proteasome inhibitor combats malaria.
    Crunkhorn S
    Nat Rev Drug Discov; 2016 Apr; 15(4):232-3. PubMed ID: 27032831
    [No Abstract]   [Full Text] [Related]  

  • 16. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
    Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
    J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First homology model of Plasmodium falciparum glucose-6-phosphate dehydrogenase: Discovery of selective substrate analog-based inhibitors as novel antimalarial agents.
    Alencar N; Sola I; Linares M; Juárez-Jiménez J; Pont C; Viayna A; Vílchez D; Sampedro C; Abad P; Pérez-Benavente S; Lameira J; Bautista JM; Muñoz-Torrero D; Luque FJ
    Eur J Med Chem; 2018 Feb; 146():108-122. PubMed ID: 29407943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structures revealing mechanisms of resistance and collateral sensitivity of Plasmodium falciparum to proteasome inhibitors.
    Hsu HC; Li D; Zhan W; Ye J; Liu YJ; Leung A; Qin J; Crespo B; Gamo FJ; Zhang H; Cui L; Roth A; Kirkman LA; Li H; Lin G
    Nat Commun; 2023 Dec; 14(1):8302. PubMed ID: 38097652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Biological Evaluation of Novel 1,2,4-Trioxanes as Potential Antimalarial Agents.
    Gupta AK; Varshney K; Kumar V; Srivastava K; Pant AB; Puri SK; Saxena AK
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28207169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Support vector machine based prediction of P. falciparum proteasome inhibitors and development of focused library by molecular docking.
    Subramaniam S; Mehrotra M; Gupta D
    Comb Chem High Throughput Screen; 2011 Dec; 14(10):898-907. PubMed ID: 21843142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.